Senzer has announced that its breath-activated Systemic inhaled Delivery Device (SiDD) inhaler has won a 2018 Good Design award in the medical category. The Good Design Awards are presented by The Chicago Athenaeum: Museum of Architecture and Design “for the most innovative and cutting-edge industrial, product, and graphiτc designs produced around the world.”
In 2015, Insys said that it had licensed Senzer’s Voke inhaler for cannabinoid products, and In April 2018, Insys announced that it planned to advance clinical research of a breath activated dronabinol (THC) inhaler. Senzer announced in July 2018 that it plans to launch its Cannafen cannabidiol inhalation solution in the UK, and the company reported data from a PK study of inhaled dronabinol in September 2018.
According to Senzer, the company intends to launch inhaled cannabinoid products for the relief of side effects of cancer treatment “into selected EU markets” this year, and FDA review of the the SiDD inhaler is underway.
Senzer Head of Design & Engineering Paul Young commented, “Recognition from such a prestigious body as Good Design is a great achievement for us, a lot of innovative thought and hard work has gone into getting the SiDD platform to this stage where we are now ready to launch into the market. We are sure that this device will bring better treatment solutions for cancer patients worldwide.”
Read the Senzer press release.
